Press Releases

PITTSBURGH, March 12, 2024 – As previously disclosed on October 1, 2023, Viatris Inc. entered into a definitive agreement with Insud Pharma, a leading Spanish multinational pharmaceutical company, to divest its women’s healthcare business, primarily related to oral and injectable contraceptives. The transaction closed on March 12, 2024. Please refer to Viatris’ Annual Report on Form 10-K for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission, for more information regarding the transaction. 

About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter).

Contacts:

MEDIA
+1.724.514.1968
Communications@viatris.com

Jennifer Mauer
Jennifer.Mauer@viatris.com

Matt Klein
Matthew.Klein@viatris.com

INVESTORS
Bill Szablewski 
+1.412.707.2866
InvestorRelations@viatris.com
William.Szablewski@viatris.com